Special Report: Medical tech company HeraMED has signed an exclusive deal to distribute its foetal heart rate monitors in Australia.

HeraMED (ASX:HMD) is accelerating its commercialisation strategy with an exclusive two-year Australian distribution agreement with APS (Advanced Pregnancy Solutions), a wholly owned subsidiary of leading Australian medical distributor, MedTech Edge.

MedTech Edge will leverage its extensive industry network to market and generate commercial exposure for HeraMED’s in-home hybrid maternity care platform, HeraCARE and its proprietary foetal heart rate monitor, HeraBEAT.

The parties will work together, targeting top-tier medical institutions and healthcare providers to amplify HeraCARE’s positioning as an innovative and comprehensive  telehealth solution and secure pilot projects ahead of signing commercial agreements.

HeraMED will supply MedTech Edge with HeraBEAT devices and HeraCARE SaaS platform for distribution across Australia in order to build its maternity service offering while expediting multiple opportunities that are present due to COVID-19.

“This agreement represents an important milestone for the company in its Australian commercialisation strategy,” said HeraMED CEO and co-founder David Groberman.

“MedTech Edge and APS have an excellent reputation and proven track record in selling innovative medical technologies,” he said.

The agreement also marks HeraMED’s shift toward a monthly subscription, platform as a service-based business model which Groberman says will be an important pivot post-COVID-19.

“The COVID-19 pandemic has resulted in fundamental changes to global healthcare systems infrastructure and Governments globally are increasingly adopting innovative telehealth and monitoring solutions for patients at home,” he said.

“HeraMED is seeing a quantum leap in the mindset and support and is well-placed to capitalise on the opportunity to fast-track adoption of digital health and homebased solutions for maternal health.”

Founded in 2013 by by renowned healthcare and medical devices sales specialist David Zarfaty, MedTech Edge specialises in the sale and distribution of state-of-the-art medical solutions across Australia and New Zealand and currently works with a number of world leading brands including Dell, ITD, eDX and Viasonix.

Zarfaty said he’s excited to be working with a cutting-edge healthcare technology company like HeraMED’s.

“This technology adds another dimension to healthcare that has been long overdue as applying digital principles to conventional treatments is an important step in ensuring healthcare does not become outdated,” he said.

“These amazing technologies, coupled with our deep knowledge of local key opinion leaders, will allow for early deployment of this technology to the benefit of clinicians as they will be able to remotely monitor the wellbeing of mothers and babies during pregnancy.”

The agreement underpins HeraMED’s Australia-focused growth strategy to become a leading telehealth solutions provider focused on the maternity market with a suite of accurate and medically validated high-tech products.

The company aims to do this by building an extensive network of strong industry relationships unpinning future commercial agreements upon the full launch of the Company’s fully integrated hybrid maternity care platform, HeraCARE in late 2020.

This story was developed in collaboration with HeraMED, a Stockhead advertiser at the time of publishing.
This story does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.